[Therapeutic effect of combined use of interferon alpha-1b, interleukin-2 and thalidomide on reversing minimal residual disease in acute myeloid leukemia].

Ruihua Mi、Lin Chen、Xudong Wei、Qingsong Yin、Minfang Wang、Lijie Liang、Fangfang Yuan、Mengjuan Li

2019PubMedMedicine被引 5开放获取

摘要

The ITI regimen can reduce the MRD level of patient with AML who are in hematologic remission but MRD-positive. The therapeutic effect could be improved by a higher dose administration of ITI regimen, and therapeutic effect may be negatively correlated with MRD level before treatment.

引用本文（GB/T 7714）

Ruihua Mi, Lin Chen, Xudong Wei, 等. [Therapeutic effect of combined use of interferon alpha-1b, interleukin-2 and thalidomide on reversing minimal residual disease in acute myeloid leukemia].[J]. PubMed, 2019.

引文网络

参考文献与被引分析加载中…

DOI：https://doi.org/10.3760/cma.j.issn.0253-2727.2019.02.004

本站仅收录题录与摘要供学习参考，全文版权归属出版方；如有侵权请联系我们删除。